Biblio
Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. Hematol Oncol Stem Cell Ther. 2023;16(4):346-350.
. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 2024.
Outcomes of TP53 Mutated AML with Evolving Frontline Therapies: Impact of Allogeneic Stem Cell Transplantation on Survival. Am J Hematol. 2022.
.